[HTML][HTML] COVID-19, asthma, and biological therapies: what we need to know
M Morais-Almeida, R Aguiar, B Martin… - World Allergy …, 2020 - Elsevier
Managing patients with severe asthma during the coronavirus pandemic and COVID-19 is a
challenge. Authorities and physicians are still learning how COVID-19 affects people with …
challenge. Authorities and physicians are still learning how COVID-19 affects people with …
SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis
P Rogliani, BL Ritondo, J Ora… - European …, 2020 - Eur Respiratory Soc
To date, there are no network meta-analyses comparing the impact of as-needed treatments
in asthma, including the single maintenance and reliever therapy (known as “SMART” or …
in asthma, including the single maintenance and reliever therapy (known as “SMART” or …
Self-administered mepolizumab in the management of severe asthma: usability and patient acceptance
R Miyokawa, C Kivler, S Louie, D Godor… - Patient preference …, 2020 - Taylor & Francis
The increasing use of advanced biologic therapies for patients with severe asthma is
transforming the standard of care, clinic workflow, and the clinic business model. Expanded …
transforming the standard of care, clinic workflow, and the clinic business model. Expanded …
Availability and reimbursement of biological products for severe asthma in Bulgaria
Objectives: This study aims to analyze the reimbursement and cost of biological therapy for
severe asthma in Bulgaria during 2014–2019 from the perspective of the National Health …
severe asthma in Bulgaria during 2014–2019 from the perspective of the National Health …
Dupilumab en el tratamiento del asma
SE Arablin-Oropeza, V González-Uribe… - Revista Alergia …, 2020 - revistaalergia.mx
Dupilumab es un anticuerpo monoclonal humano contra receptores de interleucina (IL)-4 e
IL-4/IL-13. Estas son citocinas clave en la génesis de la inflamación tipo 2, predominante en …
IL-4/IL-13. Estas son citocinas clave en la génesis de la inflamación tipo 2, predominante en …
How frequently is asthma objectively demonstrated before starting a biologic? Quality assessment of a group practice of allergists and immunologists
I Dziewa, T Craig, T Al-Shaikhly - International journal of environmental …, 2020 - mdpi.com
Worldwide, asthma-related healthcare cost remains a major burden. Individuals with severe
asthma account for 50% of that cost. Although they are expensive, biologics such as anti-IL5 …
asthma account for 50% of that cost. Although they are expensive, biologics such as anti-IL5 …
Immune modulatory effects of novel monoclonal antibodies target therapies in severe eosinophilic asthma patients
L Bergantini - 2020 - usiena-air.unisi.it
New anti IL-5 antibodies, mepolizumab and benralizumab, have recently been approved for
severe asthma, sharing the same inclusion criteria. To contribute on biomarkers research …
severe asthma, sharing the same inclusion criteria. To contribute on biomarkers research …
The role of eosinophilopoietins and integrins on eosinophils biology in asthma
J Palacionytė, A Januškevičius… - Pulmonologija ir …, 2020 - pia.pulmoalerg.lt
Astma yra uždegiminė kvėpavimo takų liga, kuria serga apie 300 milijonų žmonių visame
pasaulyje, o sergamumas nuolat didėja. Sergantiesiems astma dažniausiai nustatomas 2 …
pasaulyje, o sergamumas nuolat didėja. Sergantiesiems astma dažniausiai nustatomas 2 …
[PDF][PDF] Tresiba (inzulín degludek)–příběh třetí (aneb případ závodního cyklisty)
K Štechová - V DIABETOLOGII - geum.org
Článek prezentuje kazuistiku 22letého pacienta, který se závodně věnuje silniční cyklistice.
Pro diabetes 1. typu je léčen 10 let, je bez chronických diabetických komplikací. Od prvního …
Pro diabetes 1. typu je léčen 10 let, je bez chronických diabetických komplikací. Od prvního …